Thursday 25 October 2012

Mirabegron Receives Positive CHMP Opinion For Treatment Of Overactive Bladder Symptoms

ASTELLAS PHARMA Ltd. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the granting of a marketing authorisation for BETMIGATM (mirabegron) for the symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. The opinion now needs ratification by decision of the European Commission which is expected within the next 74-90 days... via Health News from Medical News Today Read More Here..

No comments:

Post a Comment